Production (Stage)
Acrivon Therapeutics, Inc.
ACRV
$1.17
$0.021.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.25M | 6.32M | 6.28M | 6.41M | 6.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.66M | 24.95M | 25.14M | 21.44M | 17.67M |
| Operating Income | -21.66M | -24.95M | -25.14M | -21.44M | -17.67M |
| Income Before Tax | -19.68M | -22.83M | -22.44M | -18.80M | -16.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.68M | -22.83M | -22.44M | -18.80M | -16.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.68M | -22.83M | -22.44M | -18.80M | -16.49M |
| EBIT | -21.66M | -24.95M | -25.14M | -21.44M | -17.67M |
| EBITDA | -21.35M | -24.65M | -24.89M | -21.21M | -17.44M |
| EPS Basic | -0.51 | -0.60 | -0.59 | -0.52 | -0.73 |
| Normalized Basic EPS | -0.32 | -0.39 | -0.37 | -0.33 | -0.46 |
| EPS Diluted | -0.51 | -0.60 | -0.59 | -0.52 | -0.73 |
| Normalized Diluted EPS | -0.32 | -0.39 | -0.37 | -0.33 | -0.46 |
| Average Basic Shares Outstanding | 38.35M | 38.24M | 38.11M | 36.13M | 22.59M |
| Average Diluted Shares Outstanding | 38.35M | 38.24M | 38.11M | 36.13M | 22.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |